ADVANCE 02 • Cardiometabolic
GLP-1 receptor agonists in obesity and cardiovascular risk
What is new?
Incretin-based therapy now treats obesity as a chronic biologic disease and can reduce cardiovascular events in selected high-risk patients.Mechanism / concept
GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying and increases central satiety; weight loss improves downstream metabolic load.Where it fits clinically
Type 2 diabetes, obesity/overweight meeting treatment criteria, and selected patients with established cardiovascular disease according to agent-specific evidence/labels.Key evidence and why it matters
Modern outcome trials demonstrate substantial weight reduction and cardiovascular benefit with selected agents, moving therapy beyond HbA1c-centric care.Practical physician perspective
Escalate slowly, counsel about GI effects and preserve protein intake/resistance activity during weight loss. Coordinate with insulin or sulfonylurea to reduce hypoglycaemia risk.Limitations, adverse effects & cautions
Nausea/vomiting, gallbladder events and uncommon pancreatitis; avoid inappropriate use in pregnancy and respect product-specific contraindications.Take-home: Newer medicine should change practice only when the specific drug, device or diagnostic is supported for the patient’s indication. Always verify current approval, guideline position, dose, contraindications and local availability before clinical use.
Educational update module: “Newer” is time-sensitive. Regulatory approvals and guideline positions differ by country and can change. Content is for professional learning and must not replace current prescribing information, local protocols or specialist assessment.